Oncology Reports · 1998 · 52 citations · 0 references
MedicineOncologyPharmacologyApoptosisGastrointestinal OncologyImmunotherapyAdjuvant ChemotherapyAdjuvant TherapyApoptosis In CancerGastric CancerSystemic Therapy For Gastrointestinal CancersTherapeutic Monoclonal AntibodiesApoptosis TargetingCancer Cell ApoptosisGastric Cancer Systemic TherapyHistopathological EvaluationHistopathological InterpretationHistopathological LesionsImmunotherapy For Gastric CancerMonoclonal Antibodies In Oncology
In a first clinical trial with the apoptosis-inducing human antibody SC-1 eight patients with poorly differentiated stomach adenocarcinoma of diffuse-type received 20 or 30 mg of purified SC-1 antibody intravenously, followed 24 or 48 h later by gastrectomy and lymphadenectomy. In seven cases a significant induction of apoptotic activity was measured in primary tumors as compared with earlier biopsy material and in five patients a significant regression of tumor mass could be determined histopathologically. No toxic crossreactivity was observed with normal tissue or organs of patients.